Skip to main content
Top
Published in: Endocrine 2/2016

01-11-2016 | Research Letter

Nonspecific binding of a frequently used vitamin D receptor (VDR) antibody: important implications for vitamin D research in human health

Authors: Pedro L. F. Costa, Monica M. França, Bruno Ferraz-de-Souza

Published in: Endocrine | Issue 2/2016

Login to get access

Excerpt

Amid the ongoing debate surrounding optimal vitamin D status for bone and mineral homeostasis, the investigation of extraskeletal effects of vitamin D on several aspects of human health has burgeoned in recent years [14]. Indeed, a variety of potentially beneficial actions of vitamin D have been proposed, including in areas of major public health concerns such as cancer and cardiovascular disease [57]. Besides the cumulative epidemiological evidence linking serum 25-hydroxyvitamin levels to extraskeletal outcomes, biological plausibility of these pleiotropic effects has derived from the identification of the vitamin D receptor (VDR) in numerous cells and tissues beyond those directly involved in bone metabolism [8, 9]. …
Literature
1.
go back to reference A.C. Ross, J.E. Manson, S.A. Abrams, J.F. Aloia, P.M. Brannon, S.K. Clinton, R.A. Durazo-Arvizu, J.C. Gallagher, R.L. Gallo, G. Jones, C.S. Kovacs, S.T. Mayne, C.J. Rosen, S.A. Shapses, The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J. Clin. Endocrinol. Metab. 96(1), 53–58 (2011). doi:10.1210/jc.2010-2704 CrossRefPubMed A.C. Ross, J.E. Manson, S.A. Abrams, J.F. Aloia, P.M. Brannon, S.K. Clinton, R.A. Durazo-Arvizu, J.C. Gallagher, R.L. Gallo, G. Jones, C.S. Kovacs, S.T. Mayne, C.J. Rosen, S.A. Shapses, The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J. Clin. Endocrinol. Metab. 96(1), 53–58 (2011). doi:10.​1210/​jc.​2010-2704 CrossRefPubMed
2.
go back to reference H. Fuleihan Gel, R. Bouillon, B. Clarke, M. Chakhtoura, C. Cooper, M. McClung, R.J. Singh, Serum 25-hydroxyvitamin D levels: variability, knowledge gaps, and the concept of a desirable range. J. Bone Miner. Res. 30(7), 1119–1133 (2015). doi:10.1002/jbmr.2536 CrossRef H. Fuleihan Gel, R. Bouillon, B. Clarke, M. Chakhtoura, C. Cooper, M. McClung, R.J. Singh, Serum 25-hydroxyvitamin D levels: variability, knowledge gaps, and the concept of a desirable range. J. Bone Miner. Res. 30(7), 1119–1133 (2015). doi:10.​1002/​jbmr.​2536 CrossRef
4.
go back to reference L. Cianferotti, C. Cricelli, J.A. Kanis, R. Nuti, J.Y. Reginster, J.D. Ringe, R. Rizzoli, M.L. Brandi, The clinical use of vitamin D metabolites and their potential developments: a position statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF). Endocrine 50(1), 12–26 (2015). doi:10.1007/s12020-015-0606-x CrossRefPubMed L. Cianferotti, C. Cricelli, J.A. Kanis, R. Nuti, J.Y. Reginster, J.D. Ringe, R. Rizzoli, M.L. Brandi, The clinical use of vitamin D metabolites and their potential developments: a position statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF). Endocrine 50(1), 12–26 (2015). doi:10.​1007/​s12020-015-0606-x CrossRefPubMed
15.
16.
go back to reference B. Ferraz-de-Souza, P.L.F. Costa, M.L. Katayama, E.T. Carneiro, M.A. Folgueira, M.M. França, Opposing vitamin D receptor activity in the absence of 1,25-dihydroxyvitamin D. (2016 submitted). B. Ferraz-de-Souza, P.L.F. Costa, M.L. Katayama, E.T. Carneiro, M.A. Folgueira, M.M. França, Opposing vitamin D receptor activity in the absence of 1,25-dihydroxyvitamin D. (2016 submitted).
17.
go back to reference L.T. Campos, H. Brentani, R.A. Roela, M.L. Katayama, L. Lima, C.F. Rolim, C. Milani, M.A. Folgueira, M.M. Brentani, Differences in transcriptional effects of 1α,25 dihydroxyvitamin D3 on fibroblasts associated to breast carcinomas and from paired normal breast tissues. J. Steroid Biochem. Mol. Biol. 133, 12–24 (2013). doi:10.1016/j.jsbmb.2012.08.002 CrossRefPubMed L.T. Campos, H. Brentani, R.A. Roela, M.L. Katayama, L. Lima, C.F. Rolim, C. Milani, M.A. Folgueira, M.M. Brentani, Differences in transcriptional effects of 1α,25 dihydroxyvitamin D3 on fibroblasts associated to breast carcinomas and from paired normal breast tissues. J. Steroid Biochem. Mol. Biol. 133, 12–24 (2013). doi:10.​1016/​j.​jsbmb.​2012.​08.​002 CrossRefPubMed
18.
go back to reference B. Ferraz-de-Souza, F. Martin, D. Mallet, R.E. Hudson-Davies, P. Cogram, L. Lin, D. Gerrelli, F. Beuschlein, Y. Morel, A. Huebner, J.C. Achermann, CBP/p300-interacting transactivator, with Glu/Asp-rich C-terminal domain, 2, and pre-B-cell leukemia transcription factor 1 in human adrenal development and disease. J. Clin. Endocrinol. Metab. 94(2), 678–683 (2009). doi:10.1210/jc.2008-1064 CrossRefPubMed B. Ferraz-de-Souza, F. Martin, D. Mallet, R.E. Hudson-Davies, P. Cogram, L. Lin, D. Gerrelli, F. Beuschlein, Y. Morel, A. Huebner, J.C. Achermann, CBP/p300-interacting transactivator, with Glu/Asp-rich C-terminal domain, 2, and pre-B-cell leukemia transcription factor 1 in human adrenal development and disease. J. Clin. Endocrinol. Metab. 94(2), 678–683 (2009). doi:10.​1210/​jc.​2008-1064 CrossRefPubMed
Metadata
Title
Nonspecific binding of a frequently used vitamin D receptor (VDR) antibody: important implications for vitamin D research in human health
Authors
Pedro L. F. Costa
Monica M. França
Bruno Ferraz-de-Souza
Publication date
01-11-2016
Publisher
Springer US
Published in
Endocrine / Issue 2/2016
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-016-1036-0

Other articles of this Issue 2/2016

Endocrine 2/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.